{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:09:52Z","timestamp":1791389392599,"version":"4.3.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04210-9","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:28:03Z","timestamp":1770391683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor"],"prefix":"10.1186","volume":"26","author":[{"given":"Mao","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Badehnoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4210_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020. https:\/\/doi.org\/10.3390\/medsci8010015.","journal-title":"Med Sci"},{"key":"4210_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4210_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017;198:552\u20139.","journal-title":"J Urol"},{"key":"4210_CR4","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1002\/mco2.455","volume":"4","author":"M Peng","year":"2023","unstructured":"Peng M, Chu X, Peng Y, Li D, Zhang Z, Wang W, et al. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges. MedComm. 2023;4:e455.","journal-title":"MedComm"},{"key":"4210_CR5","first-page":"384","volume":"9","author":"T Pan","year":"2021","unstructured":"Pan T, Lehman E, Raman JD. Performance characteristics of urinary cytology in patients presenting with gross and microscopic hematuria. Am J Clin Exp Urol. 2021;9:384\u20139.","journal-title":"Am J Clin Exp Urol"},{"key":"4210_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PAI.0000000000000872","volume":"29","author":"KA Lombardo","year":"2021","unstructured":"Lombardo KA, Murati Amador B, Parimi V, Hoffman-Censits J, Choi W, Hahn NM, et al. Urothelial carcinoma in situ of the bladder: correlation of CK20 expression with adaptive immune resistance, response to BCG therapy, and clinical outcome. Applied immunohistochemistry & molecular morphology\u202f: AIMM. 2021;29:127\u201335.","journal-title":"Applied immunohistochemistry & molecular morphology : AIMM"},{"key":"4210_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.eururo.2022.02.028","volume":"81","author":"R Mayr","year":"2022","unstructured":"Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, et al. Prognostic and predictive value of fibroblast growth factor receptor alterations in high-grade non\u2013muscle-invasive bladder cancer treated with and without Bacillus Calmette-Gu\u00e9rin immunotherapy. Eur Urol. 2022;81:606\u201314.","journal-title":"Eur Urol"},{"key":"4210_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081536","volume":"16","author":"A Tamalunas","year":"2024","unstructured":"Tamalunas A, Aydogdu C, Unterrainer LM, Schott M, Rodler S, Ledderose S, et al. The vanishing clinical value of PD-L1 status as a predictive biomarker in the first-line treatment of urothelial carcinoma of the bladder. Cancers. 2024;16:1536.","journal-title":"Cancers"},{"key":"4210_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","volume":"5","author":"J Chou","year":"2022","unstructured":"Chou J, Trepka K, Sj\u00f6str\u00f6m M, Egusa EA, Chu CE, Zhu J, et al. TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells. Eur Urol Oncol. 2022;5:714\u20138.","journal-title":"Eur Urol Oncol"},{"key":"4210_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105.","journal-title":"Genes Cancer"},{"key":"4210_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","volume":"2","author":"R Sultana","year":"2024","unstructured":"Sultana R, Chen S, Lim EH, Dent R, Chowbay B. Efficacy and safety of sacituzumab Govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis. BJC Rep. 2024;2:85.","journal-title":"BJC Rep"},{"key":"4210_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/dvdy.24242","volume":"244","author":"AR McDougall","year":"2015","unstructured":"McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015;244:99\u2013109.","journal-title":"Dev Dyn"},{"key":"4210_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84.","journal-title":"Genes Cancer"},{"key":"4210_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59:701\u201310.","journal-title":"J Histochem Cytochem"},{"key":"4210_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"X Liu","year":"2022","unstructured":"Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296.","journal-title":"Pharmacol Ther"},{"key":"4210_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332489","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.","journal-title":"Front Immunol"},{"key":"4210_CR17","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","volume":"78","author":"M Lipinski","year":"1981","unstructured":"Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4210_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6890-12-22","volume":"12","author":"E Bignotti","year":"2012","unstructured":"Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol. 2012;12:1\u20139.","journal-title":"BMC Clin Pathol"},{"key":"4210_CR19","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-12-3266","volume":"73","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating \u03b21 integrin functions. Cancer Res. 2013;73:3155\u201367.","journal-title":"Cancer Res"},{"key":"4210_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/emmm.201200222","volume":"4","author":"JC Lin","year":"2012","unstructured":"Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4:472\u201385.","journal-title":"EMBO Mol Med"},{"key":"4210_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bbcan.2009.08.001","volume":"1796","author":"R Cubas","year":"2009","unstructured":"Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2009;1796:309\u201314.","journal-title":"Biochim Et Biophys Acta (BBA)-Reviews Cancer"},{"key":"4210_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pep.2013.07.006","volume":"91","author":"T Vidmar","year":"2013","unstructured":"Vidmar T, Pav\u0161i\u010d M, Lenar\u010di\u010d B. Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain. Protein Expr Purif. 2013;91:69\u201376.","journal-title":"Protein Expr Purif"},{"key":"4210_CR23","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s162447","author":"S Zaman","year":"2019","unstructured":"Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019. https:\/\/doi.org\/10.2147\/ott.s162447.","journal-title":"Onco Targets Ther"},{"key":"4210_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi A, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222\u201333.","journal-title":"Oncogene"},{"key":"4210_CR25","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/onc.2012.151","volume":"32","author":"E Guerra","year":"2013","unstructured":"Guerra E, Trerotola M, Aloisi A, Tripaldi R, Vacca G, La Sorda R, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32:1594\u2013600.","journal-title":"Oncogene"},{"key":"4210_CR26","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1158\/0008-5472.CAN-04-4059","volume":"65","author":"DR Wonsey","year":"2005","unstructured":"Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005;65:5181\u20139.","journal-title":"Cancer Res"},{"key":"4210_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1161\/CIRCRESAHA.108.190751","volume":"104","author":"L Yuan","year":"2009","unstructured":"Yuan L, Nikolova-Krstevski V, Zhan Y, Kondo M, Bhasin M, Varghese L, et al. Antiinflammatory effects of the ETS factor ERG in endothelial cells are mediated through transcriptional repression of the interleukin-8 gene. Circ Res. 2009;104:1049\u201357.","journal-title":"Circ Res"},{"key":"4210_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.022","author":"A Bankhead","year":"2020","unstructured":"Bankhead A, McMaster T, Wang Y, Boonstra PS, Palmbos PL. TP63 isoform expression is linked with distinct clinical outcomes in cancer. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.022.","journal-title":"EBioMedicine"},{"key":"4210_CR29","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1074\/jbc.RA119.008084","volume":"294","author":"Y Mori","year":"2019","unstructured":"Mori Y, Akita K, Ojima K, Iwamoto S, Yamashita T, Morii E, et al. Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C \u03b1\/\u03b4 (PKC\u03b1\/\u03b4) enhances cell motility. J Biol Chem. 2019;294:11513\u201324.","journal-title":"J Biol Chem"},{"key":"4210_CR30","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.neo.2021.07.002","volume":"23","author":"E Guerra","year":"2021","unstructured":"Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Vacca G, et al. Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer. Neoplasia. 2021;23:898\u2013911.","journal-title":"Neoplasia"},{"key":"4210_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505\u201318.","journal-title":"Nat Rev Cancer"},{"key":"4210_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/excr.1999.4667","volume":"253","author":"R Baserga","year":"1999","unstructured":"Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253:1\u20136.","journal-title":"Exp Cell Res"},{"key":"4210_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2018.10.039","volume":"152","author":"ST Sin","year":"2019","unstructured":"Sin ST, Li Y, Liu M, Ma S, Guan X-Y. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol. 2019;152:185\u201393.","journal-title":"Gynecol Oncol"},{"key":"4210_CR34","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1158\/1078-0432.CCR-15-1701","volume":"22","author":"E Guerra","year":"2016","unstructured":"Guerra E, Trerotola M, Tripaldi R, Aloisi AL, Simeone P, Sacchetti A, et al. Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors. Clin Cancer Res. 2016;22:4197\u2013205.","journal-title":"Clin Cancer Res"},{"key":"4210_CR35","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/jcp.24074","volume":"227","author":"M Trerotola","year":"2012","unstructured":"Trerotola M, Li J, Alberti S, Languino LR. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the \u03b21 integrin\u2010RACK1 axis. J Cell Physiol. 2012;227:3670\u20137.","journal-title":"J Cell Physiol"},{"key":"4210_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:1\u201313.","journal-title":"Mol Cancer"},{"key":"4210_CR37","doi-asserted-by":"publisher","first-page":"20882","DOI":"10.1073\/pnas.0811411106","volume":"105","author":"AS Goldstein","year":"2008","unstructured":"Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA. 2008;105:20882\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4210_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.1189992","volume":"329","author":"AS Goldstein","year":"2010","unstructured":"Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010;329:568\u201371.","journal-title":"Science"},{"key":"4210_CR39","doi-asserted-by":"crossref","unstructured":"Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. 2009. 136(11):1951-60.","DOI":"10.1242\/dev.031369"},{"key":"4210_CR40","doi-asserted-by":"publisher","first-page":"17298","DOI":"10.1073\/pnas.1012548107","volume":"107","author":"S Memarzadeh","year":"2010","unstructured":"Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T, et al. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci USA. 2010;107:17298\u2013303.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4210_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658","volume":"6","author":"P Zeng","year":"2016","unstructured":"Zeng P, Chen M-B, Zhou L-N, Tang M, Liu C-Y, Lu P-H. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.","journal-title":"Sci Rep"},{"key":"4210_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59:701\u201310.","journal-title":"J Histochem Cytochem"},{"key":"4210_CR43","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/CMAR.S147033","volume":"9","author":"P Xu","year":"2017","unstructured":"Xu P, Zhao Y, Liu K, Lin S, Liu X, Wang M, et al. Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas. Cancer Manag Res. 2017;9:821\u201337.","journal-title":"Cancer Manag Res"},{"key":"4210_CR44","first-page":"3820","volume":"15","author":"P Zhao","year":"2018","unstructured":"Zhao P, Zhang Z. TNF-\u03b1 promotes colon cancer cell migration and invasion by upregulating TROP-2. Oncol Lett. 2018;15:3820\u20137.","journal-title":"Oncol Lett"},{"key":"4210_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/onc.2013.13","volume":"33","author":"H Nakanishi","year":"2014","unstructured":"Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T, et al. Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene. 2014;33:702\u201312.","journal-title":"Oncogene"},{"key":"4210_CR46","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","volume":"8","author":"T Liu","year":"2013","unstructured":"Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013;8:e75864.","journal-title":"PLoS One"},{"key":"4210_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.","journal-title":"Mol Cancer"},{"key":"4210_CR48","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1073\/pnas.1603645113","volume":"113","author":"JW Park","year":"2016","unstructured":"Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, et al. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci. 2016;113:4482\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"4210_CR49","doi-asserted-by":"publisher","first-page":"20111","DOI":"10.1073\/pnas.1320565110","volume":"110","author":"T Stoyanova","year":"2013","unstructured":"Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci USA. 2013;110:20111\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4210_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1342367","volume":"13","author":"JH M\u00fcller","year":"2023","unstructured":"M\u00fcller JH, Plage H, Elezkurtaj S, Mandelkow T, Huang Z, Lurati MCJ, et al. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas. Front Oncol. 2023;13:1342367.","journal-title":"Front Oncol"},{"key":"4210_CR51","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14114","volume":"26","author":"M Abbas","year":"2023","unstructured":"Abbas M, Heitplatz B, Bernemann C, Boegemann M, Trautmann M, Schrader AJ, et al. Immunohistochemical expression of TROP\u20112 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. Oncol Lett. 2023;26:527.","journal-title":"Oncol Lett"},{"key":"4210_CR52","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-937","volume":"116","author":"M Brunelli","year":"2024","unstructured":"Brunelli M, Gobbo S, Malpeli G, Sirgiovanni G, Caserta C, Munari E, et al. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. Pathologica. 2024;116:55.","journal-title":"Pathologica"},{"key":"4210_CR53","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5c00069","author":"W Huang","year":"2025","unstructured":"Huang W, Wang T, Chao F, Yang Q, Mixdorf JC, Li L, et al. ImmunoPET imaging of Trop2 expression in bladder cancer using [64Cu]Cu-NOTA-Trodelvy. Mol Pharm. 2025. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00069.","journal-title":"Mol Pharm"},{"key":"4210_CR54","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.21037\/tau-22-457","volume":"11","author":"E Tomiyama","year":"2022","unstructured":"Tomiyama E, Fujita K, Hashimoto M, Adomi S, Kawashima A, Minami T, et al. Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review. Transl Androl Urol. 2022;11:1747\u201361.","journal-title":"Transl Androl Urol"},{"key":"4210_CR55","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/curroncol29060312","volume":"29","author":"E Tomiyama","year":"2022","unstructured":"Tomiyama E, Fujita K, Nakano K, Kuwahara K, Minami T, Kato T, et al. Trop-2 in upper tract urothelial carcinoma. Curr Oncol. 2022;29:3911\u201321.","journal-title":"Curr Oncol"},{"key":"4210_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216246","volume":"566","author":"C Chen","year":"2023","unstructured":"Chen C, Chao Y, Zhang C, Hu W, Huang Y, Lv Y, et al. TROP2 translation mediated by dual m(6)A\/m(7)G RNA modifications promotes bladder cancer development. Cancer Lett. 2023;566:216246.","journal-title":"Cancer Lett"},{"key":"4210_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100753","author":"G Dernbach","year":"2025","unstructured":"Dernbach G, Eich M-L, Dragomir MP, Anders P, Jurczok N, Stief C, et al. Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management. Mod Pathol. 2025. https:\/\/doi.org\/10.1016\/j.modpat.2025.100753.","journal-title":"Mod Pathol"},{"key":"4210_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae161","author":"KB Case","year":"2024","unstructured":"Case KB, Martini DJ, Dababneh MN, Bidot S, Nazha B, Brown J, et al. Trop-2 and ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. Am J Clin Pathol. 2024. https:\/\/doi.org\/10.1093\/ajcp\/aqae161.","journal-title":"Am J Clin Pathol"},{"key":"4210_CR59","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","volume":"30","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Balar AV, Petrylak DP, Kalebasty AR, Grivas P, Fl\u00e9chon A, et al. Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer. Clin Cancer Res. 2024;30:3179\u201388.","journal-title":"Clin Cancer Res"},{"key":"4210_CR60","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","volume":"21","author":"F Ghali","year":"2023","unstructured":"Ghali F, Vakar-Lopez F, Roudier MP, Garcia J, Arora S, Cheng HH, et al. Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: a rapid autopsy study. Clin Genitourin Cancer. 2023;21:669\u201378.","journal-title":"Clin Genitourin Cancer"},{"key":"4210_CR61","first-page":"515","volume":"53","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yang G, Zhang R, Dong L, Chen H, Bo J, et al. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncol. 2018;53:515\u201326.","journal-title":"Int J Oncol"},{"key":"4210_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.32074\/1591-951X-937","volume":"116","author":"M Brunelli","year":"2024","unstructured":"Brunelli M, Gobbo S, Malpeli G, Sirgiovanni G, Caserta C, Munari E, et al. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. Pathologica. 2024;116:55\u201361.","journal-title":"Pathologica"},{"key":"4210_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530.","journal-title":"Cancer Treat Rev"},{"key":"4210_CR64","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/ajco.13024","volume":"15","author":"Y Mi","year":"2019","unstructured":"Mi Y, Zhao Y, Shi F, Zhang M, Wang C, Liu X. Diagnostic accuracy of urine cytokeratin 20 for bladder cancer: a meta-analysis. Asia-Pac J Clin Oncol. 2019;15:e11-9.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"4210_CR65","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00345-020-03498-0","volume":"39","author":"M Rouanne","year":"2021","unstructured":"Rouanne M, Radulescu C, Adam J, Allory Y. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol. 2021;39:1345\u201355.","journal-title":"World J Urol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04210-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:02:38Z","timestamp":1773147758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4210"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04210-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}